The US Food and Drug Administration announced the launch of Elsa, a generative AI tool aimed at improving the efficiency of various operations, including scientific reviews. Currently, the FDA is already using ELSA to speed up clinical protocol review, shorten the time required for scientific evaluation, and identify high-priority audit targets. The FDA said Elsa provides a secure platform for FDA employees to access internal documents while ensuring that all information remains within the agency. These models are not trained with data submitted by regulated industries to protect sensitive research and data handled by FDA personnel. The regulator said in May that after the trial phase, the artificial intelligence system will be fully integrated by June 30.

The US Food and Drug Administration announced the launch of Elsa, a generative AI tool aimed at improving the efficiency of various operations, including scientific reviews. Currently, the FDA is already using ELSA to speed up clinical protocol review, shorten the time required for scientific evaluation, and identify high-priority audit targets. The FDA said Elsa provides a secure platform for FDA employees to access internal documents while ensuring that all information remains within the agency. These models are not trained with data submitted by regulated industries to protect sensitive research and data handled by FDA personnel. The regulator said in May that after the trial phase, the artificial intelligence system will be fully integrated by June 30.